Elixinol Wellness Annual Report 2021

NOTE 36: SHARE¨BASED PAYMENTS CONTINUED 2020 Grant date Expiry date Balance at the start of the year Granted Exercised Expired/ forfeited/ other Balance at the end of the year ¢©/¢£/§¢¡¥ ¢©/¢¤/§¢§© ¡£¨,¡¥¡ – – (¥¥,¨«¤) ª¢,§§£ ¡«/¢«/§¢¡¥ ¡«/¢¥/§¢§© ¡,ª«¢,¢¢¢ – – (¡,§¢¢,¢¢¢) £«¢,¢¢¢ ¢¡/¡¡/§¢¡¥ ¢¡/¢§/§¢§£ ¡©¢,¡¨£ – – (¡©¢,¡¨£) – §©/¢«/§¢¡¨ §©/¢¥/§¢§£ £«¢,¢¢¢ – – (£«¢,¢¢¢) – §¡/¢¨/§¢¡¨ §¡/¡§/§¢§£ §««,¥¡¢ – – (§§¢,ª££) ©«,¡ªª ©¢/¢¤/§¢§¢ ©¢/¡¢/§¢§« – ¨©¤,«¢¢ – – ¨©¤,«¢¢ ©¢/¢¤/§¢§¢ ©¢/¡¢/§¢§« – ¡,«§¤,«£© – (¡¤¢,ª§¢) ¡,©«ª,¨§© ¡ª/¡¢/§¢§¢ ¢§/¢¡/§¢§ª – ¡,§©£,¡¤¤ – – ¡,§©£,¡¤¤ ,, ,¡¡,¢ – (,¢,¤) ¤,¢¦,¡¡¢ The weighted average remaining contractual life of performance rights outstanding at the end of the financial year was 3.65 years (31 December 2020: 3.97 years). For the performance rights granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows: Grant date Expiry date Share price at grant date Expected volatility* Dividend yield Risk-free interest rate* Fair value at grant date ¢¤/¢¤/§¢§¡ ¢¤/¡¢/§¢§ª ½¢.¡¡« ¨«.ª¢% – – ½¢.¢¤ª * Where no % is stated there are no market vesting conditions attached to the performance rights and vesting condition includes continuity of service. Volatilities, betas and correlations (all using the equally weighted model) are calculated using the Stambaugh method, which handles assets with short price histories (e.g. newly listed stocks) without truncating the histories of all the assets to match the number of prices for the assets with the shortest history. NOTE 37: EVENTS AFTER THE REPORTING PERIOD No matter or circumstance has arisen since 31 December 2021 that has significantly a´ected, or may significantly a´ect the Group’s operations, the results of those operations, or the Group’s state of a´airs in future financial years. F INANCI AL REPORT 75 Company Overview Financial Report Shareholder Information Key Achievements and Milestones FY2021 Highlights